Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of DNL593 in Healthy Participants and Frontotemporal Dementia
2023-508697-28-00Phase 2Authorised
- Sponsor
- Denali Therapeutics Inc.
- Start
- May 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of DNL593 in frontotemporal dementia (FTD) (5 arms), sponsored by Denali Therapeutics Inc. Primary endpoints: Incidence, severity, and seriousness of treatment-emergent adverse events and Change from baseline in safety assessments. Planned start May 2024; status: authorised.
02
Drugs
DNL593
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on 2023-508697-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508697-28-00.